The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach
The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
The placebo response is a major issue in clinical trials for psychiatric disorders. Possible contributing factors to this problem include diagnostic misclassification, issues concerning inclusion/exclusion criteria, outcome measures’ lack of sensitivity to change, measurement errors, poor quality of data entry and verification, waxing and waning of the natural course of illness, regression toward the mean phenomenon, patient and clinician expectations about the trial, study design issues, non-specific therapeutic effects, and high attrition. Over the past few decades, researchers have attempted to reduce the placebo effect in a variety of ways. Unfortunately, approaches with very little or no benefit have included restricting enrollment to selected populations, rater training, requirement of same rater, and placebo lead-in phases. Some benefits, although often marginal, have been derived from standardizing diagnostic procedures, managing clinicians’ overestimation of change, simplification of study visits and assessments, minimizing non-specific, therapeutic effects, extending trial duration, reducing number of sites, increasing the sensitivity of outcome measures, and reducing the number of treatment arms. Thus far, there has been no attempt to develop new study designs aimed at reducing the placebo effect. We are proposing a novel study design, called ‘Sequential Parallel Comparison Design’, suitable for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for such trials. Its usefulness in clinical research needs to be tested empirically. If this study design were to be found to meet its stated goals, this could markedly facilitate the process of clinical development of new compounds for the treatment of psychiatric disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Strategies to mitigate placebo response include increasing study duration, randomizing the run-in period, and addressing functional blinding in rapid-acting antidepressant trials [162]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [162]
Citations
Cites
Linear Statistical Inference and its Applications: Second Editon
Rao, C. R. (1973) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316436 · Cited by 10,489
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 1×
“These numbers are even more impressive as most negative trials are typically unpublished, suggesting that the average placebo response rate in MDD trials is probably closer to the 35–45p range.Similarly, in smoking cessation trials, the placebo response rate has progressively increased. For example, in a recent study…”
ResultIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
A Primer on Regression Artifacts
Campbell, D. T., & Kenny, D. A. (1999) · Medical Entomology and Zoology · Cited by 482
Hypericum Depression Trial Study Group (2002) · JAMA · doi:10.1001/jama.287.14.1807 · Cited by 480
Linear Statistical Inference and its Applications.
Moore, P. G., & Rao, C. R. (1967) · The Statistician · doi:10.2307/2987205 · Cited by 439
Rush, A. J., Carmody, T., & Reimitz, P. (2000) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.79 · Cited by 427 · cited 1×
“Another useful approach is to use outcome measures that can be administered in both clinician- and patient-rated forms, as in the case of the Inventory of Depressive Symptomatology (IDS) [”
MethodThe Hamilton Depression Scale: EVALUATION OF OBJECTIVITY USING LOGISTIC MODELS
Bech, P., Allerup, P., Gram, L. F., Reisby, N., Rosenberg, R., Jacobsen, O., & Nagy, A. (1981) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1981.tb00676.x · Cited by 425
Effectiveness of St John's Wort in Major Depression: A Randomized Controlled Trial
Shelton, R. C., Keller, M. B., Gelenberg, A., Dunner, D. L., Hirschfeld, R., Thase, M. E., Russell, J., Lydiard, R. B., Crits-Christoph, P., Gallop, R., et al. (2001) · JAMA · doi:10.1001/jama.285.15.1978 · Cited by 382
The Effectiveness of the Nicotine Patch for Smoking Cessation: A Meta-analysis
Fiore, M. C. (1994) · JAMA · doi:10.1001/jama.1994.03510480064036 · Cited by 345
Major depressive subtypes and treatment response
Fava, M., Uebelacker, L. A., Alpert, J. E., Nierenberg, A. A., Pava, J. A., & Rosenbaum, J. F. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00440-4 · Cited by 247 · cited 1×
“showing that the number of patients responding to placebo in MDD trials was significantly positively related to the prorated minimum Hamilton Rating Scale for Depression (HAM-D) score required to entry into such studies (r = 0.27; p = 0.03). Once again, a reasonable explanation for such findings is that pressure to en…”
BackgroundInfluentialThe responsiveness of the Hamilton Depression Rating Scale
Faries, D., Herrera, J., Rayamajhi, J., DeBrota, D., Demitrack, M., & Potter, W. Z. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00037-0 · Cited by 232 · cited 1×
“This may reduce its ability to detect differences between treatments, in particular, changes in core symptoms of depression. Two meta-analyses were conducted to compare the responsiveness of the HAM-D total score with several published unidimensional subscale scores of the HAM-D based upon core symptoms of depression [”
MethodExactly what does the Hamilton depression rating scale measure?
Gibbons, R. D., Clark, D. C., & Kupfer, D. J. (1993) · Journal of Psychiatric Research · doi:10.1016/0022-3956(93)90037-3 · Cited by 223
Identification of True Drug Response to Antidepressants: Use of Pattern Analysis
Quitkin, F. M. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790190056007 · Cited by 221
Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?
Trivedi, M. H., & Rush, J. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.63 · Cited by 175
Use of placebo control groups in evaluating efficacy of treatment of unipolar major depression
Schatzberg, A. F., & KRAEMER, H. C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00846-5 · Cited by 146 · cited 1×
“The purpose of a double-blind, placebo-controlled trial is to compare the efficacy of a specific treatment or treatments with that of placebo for patients identified according to a priori criteria. The typical design of such a trial involves the parallel comparison of one ore more treatments with placebo, with sample…”
MethodAre There Differences Between Women’s and Men’s Antidepressant Responses?
Quitkin, F. M., Stewart, J. W., McGrath, P. J., Taylor, B. P., Tisminetzky, M. S., Petkova, E., Chen, Y., Ma, G., & Klein, D. F. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1848 · Cited by 146
Sensitivity of the six‐item Hamilton Depression Rating Scale
O'Sullivan, R. L., D, M. F. M., Agustin, C., Baer, L., & Rosenbaum, J. F. (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb09649.x · Cited by 143
Information, compliance and side‐effects: a study of patients on antidepressant medication.
Myers, E. D., & Calvert, E. J. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb04993.x · Cited by 113
Two Dosages of Imipramine in Hospitalized Endogenous and Neurotic Depressives
Simpson, G. M., Lee, J. H., Cuculic, Z., & Kellner, R. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770090083008 · Cited by 106
Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment.
NIAURA, R. S., Spring, B. J., Borrelli, B., Hedeker, D., Goldstein, M. G., Keuthen, N. J., DePue, J. D., Kristeller, J. L., Ockene, J., Prochazka, A. V., et al. (2002) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.70.4.887 · Cited by 96
Kobak, K. A., Greist, J. H., Jefferson, J. W., Mundt, J. C., & Katzelnick, D. J. (1999) · PubMed · Cited by 95
Melancholic/endogenous depression and response to somatic treatment and placebo
Peselow, E. D., Sanfilipo, M. P., Difiglia, C., & Fieve, R. R. (1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.10.1324 · Cited by 82
The problem of measurement error in multisite clinical trials.
Demitrack, M. A., Faries, D., Herrera, J. M., DeBrota, D. J., & Potter, W. Z. (1998) · PubMed · Cited by 77
The Double-Blind Variable Placebo Lead-in Period: Results From Two Antidepressant Clinical Trials
Faries, D. E., Heiligenstein, J. H., Tollefson, G. D., & Potter, W. Z. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200112000-00004 · Cited by 76
Traditional and Alternative Research Designs and Methods in Clinical Pediatric Psychopharmacology
D, M. F. M. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00016 · Cited by 56 · cited 1×
“One may argue that the rigid use of standard trial designs has in fact contributed to the placebo problem and has prevented investigators from exploring and testing novel approaches to study design [”
BackgroundConcerns About Clinical Drug Trials
Robinson, D. S., & Rickels, K. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00001 · Cited by 56
Conducting Research with Children: Legal and Ethical Issues
Glantz, L. H. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00015 · Cited by 53
Assay Sensitivity, Failed Clinical Trials, and the Conduct of Science
Otto, M. W., & Nierenberg, A. A. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000064813 · Cited by 42 · cited 1×
“The article will review possible contributing factors to the placebo response and proposed remedies, and will also outline a novel study design for double-blind, placebo-controlled trials in psychiatric disorders. This design is aimed at reducing both the overall placebo response rate and the sample size required for…”
BackgroundKRAEMER, H. C., Pruyn, J. P., Gibbons, R. D., Greenhouse, J. B., Grochocinski, V. J., Waternaux, C., & Kupfer, D. J. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800240070011 · Cited by 40
Intensive design in evaluating anxiolytic agents
UHLENHUTH, E. H., Turner, D. A., Purchatzke, G., Gift, T. E., & Chassan, J. (1977) · Psychopharmacology · doi:10.1007/bf00426604 · Cited by 19
Methodology of measuring the efficacy of antidepressants
Quitkin, F. M. (1992) · Psychopharmacology · doi:10.1007/bf02246244 · Cited by 19
Research works printed but not linked: 2
- 10.1001/jama.271.24.1940 · doi:10.1001/jama.271.24.1940 · Paper page
- 10.1037//0022-006x.70.4.887 · doi:10.1037//0022-006x.70.4.887
Cited by
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Report by the ACNP Task Force on Response and Remission in Major Depressive Disorder
Rush, A. J., Kraemer, H. C., Sackeim, H. A., Fava, M., Trivedi, M. H., Frank, E., Ninan, P. T., Thase, M. E., Gelenberg, A. J., Kupfer, D. J., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301131 · Cited by 707
“Regression to the mean may further foster the invalid impression of symptomatic improvement (Fava et al, 2003a).”
Background(2020) · doi:10.1056/nejmra1907805 · Cited by 634
Tohen, M., Frank, E., Bowden, C. L., Colom, F., Ghaemi, S. N., Yatham, L. N., Malhi, G. S., Calabrese, J. R., Nolen, W. A., Vieta, E., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00726.x · Cited by 513
“Of note, when using symptom severity as a clinical trial inclusion criterion, if the same scale is used to measure symptoms at baseline and to determine entry into the study (above a certain threshold on a symptom rating scale), regression to the mean will further contribute to the invalid impression of symptomatic im…”
MethodPrognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Metadata
- Authors
- Fava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A.
- Affiliations
- Harvard University (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 72
- Issue
- 3
- Pages
- 115-127
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2073526412
- Cited by
- 452
- References
- 34
- Citations by year
- 2026: 15 · 2025: 22 · 2024: 17 · 2023: 18 · 2022: 21 · 2021: 16 · 2020: 29 · 2019: 41 · 2018: 23 · 2017: 32 · 2016: 21 · 2015: 29 · 2014: 22 · 2013: 21 · 2012: 22
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Keywords
- placebo response, placebo effect, mental illness, clinical trial design, regression to the mean, attrition, sample size reduction, outcome measure sensitivity
- MeSH terms
- Mental Disorders, Clinical Trials as Topic, Double-Blind Method, Humans, Research Design, Reproducibility of Results, Placebo Effect
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.